Document:

QuickLinks
 -- Click here to rapidly navigate through this document

Exhibit 10.14  

 
  AMENDED AND RESTATED TECHNOLOGY ACQUISITION AGREEMENT    
    

        This Amended and Restated Technology Acquisition Agreement (the "Agreement") is entered into effective as of the 14th day of March, 1996, by and between Nicholas
Kowanko, Ph.D. of 618 South Fifth Street, Moorhead, Minnesota 56560 ("Dr. Kowanko") and CryoLife, Inc. of 2211 New Market Parkway, Suite 142, Marietta,
Georgia 30067 ("CryoLife"). 

        WHEREAS,
Dr. Kowanko has invented and may develop in the future, pursuant to his services under this Agreement, certain Trade Secrets, Know-How and Patents (as defined below and
collectively referred to as the "Technology") related to methods, procedures, and sciences for creating a bioadhesive ("Adhesive") which is more particularly described in  Exhibit A attached hereto;

        WHEREAS,
Dr. Kowanko is the owner of all right, title, and interest in and to the Technology; 

        WHEREAS,
CryoLife desires to acquire the Technology in order to continue its product development and eventually commercialize products utilizing the Technology and to obtain certain
assistance from Dr. Kowanko; 

        WHEREAS,
the parties entered into a Technology Acquisition Agreement (the "TA Agreement") on March 14, 1996 to transfer the Technology and provide for Dr. Kowanko's
assistance upon the terms and conditions set forth therein; and 

        WHEREAS,
the parties desire to amend the TA Agreement in certain particulars by entering into this Agreement, which Agreement the parties intend to supersede the original TA Agreement. 

        NOW,
THEREFORE, in consideration of the premises, the promises hereinafter set forth, and other valuable consideration the receipt and sufficiency of which are hereby acknowledged, the
parties agree as follows: 

        I.    Definitions.    The following terms shall have the following meanings when used in this Agreement: 

        A.    "Improvements"
shall mean any and all (i) changes or enhancements to the Adhesive (including, without limitation, formulation changes to reduce Adhesive and
component toxicity), (ii) new bioadhesive inventions, and (iii) information relating to any delivery devices for the Adhesive, developed by Dr. Kowanko pursuant to his services
under this Agreement. 

        B.    "Know-How"
shall mean any and all non-confidential information relating to the Adhesive or its formulation currently owned by Dr. Kowanko or developed by
Dr. Kowanko pursuant to his services under this Agreement. 

        C.    "Patent(s)"
shall mean any and all domestic and foreign patents or patent applications of Dr. Kowanko, which relates to the Adhesive or its formulation, or which
may in the future be filed on the Trade Secrets or Know-How, including, without limitation, U.S. Patent No. 5385606. The term Patent(s) also shall include any and all U.S. or foreign divisions,
continuations, continuation-in-part, substitutions, reissues, and extensions of said Patent(s). 

        D.    "Technology"
shall mean the Know-How, Patent(s), Trade Secrets, and Improvements. 

        E.    "Trade
Secrets" shall mean any and all confidential information, relating to the Adhesive or its formulation currently owned by Dr. Kowanko or developed by
Dr. Kowanko pursuant to his services under this Agreement. 

        II.    Assignment of Technology.    Dr. Kowanko hereby sells, assigns, and transfers, and agrees to sell,
assign, and transfer all of his right, title, and interest in and to the Technology to CryoLife. Dr. Kowanko agrees to execute such further documents and instruments as CryoLife may reasonably
request in order to further evidence the transfer of the Technology as contemplated hereunder. 

        III.    Purchase Price.    

        A.    Purchase Price.    CryoLife shall pay Dr. Kowanko the sum of $1,200,000 (the "Purchase Price") for the
assignment of the Technology. The Purchase Price shall be payable as follows: $290,000 shall be payable
upon execution of this Agreement (which amount has been paid) and the balance shall be payable (i) in three equal installments of $290,000 each of the first, second, and third anniversaries of
the date of this Agreement and (ii) one final installment of $40,000 on the fourth anniversary of the date of this Agreement. The Purchase Price shall also include a 1.7% royalty on Net
Revenues (gross revenues minus sales tax, returns, discounts, freight and return freight, if any) from future commercial sales of the Adhesive by CryoLife which exceed $25 million in the
aggregate. In the case where the right to sell Adhesive is licensed to a third party, the royalty rate shall be computed, at CryoLife's discretion, as 1.7% of the Net Revenues of the licensee from
commercial sales of the Adhesive or as 10% of CryoLife's revenues from the licensee (in which later event, CryoLife will not be obliged to pay a 1.7% royalty based on its licensee's sales of
Adhesives). The first payment of royalties shall be due within 90 days after the end of the calendar year in which CryoLife first generates revenues from the Adhesive in excess of
$25 million in the aggregate and shall be accompanied by a written report showing all Net Revenues and royalties accrued during the preceding calendar year. Royalty payments and written reports
shall be made and furnished annually thereafter. Notwithstanding the foregoing, the royalty portion of the Purchase Price shall not be payable at any time after, if ever, the Patents expire or are
declared invalid by a court of law and such judgment is not overruled. If CryoLife chooses to license the Adhesive to a third party for a lump sum or fixed payment (as opposed to a royalty) before an
aggregate of $25 million in commercial sales has been reached, it must condition sub-licensing on accurate accounting by the licensee on an annual basis of all net revenues received from sales
of the Adhesive. CryoLife must add these accounting figures to all sales from other sources for purposes of computing aggregate sales and the computation of amounts owed to Dr. Kowanko. 

        B.    Consulting Fee.    For so long as Dr. Kowanko provides consulting services pursuant to Section 9
below, Dr. Kowanko shall receive a consulting fee of $10,000 per year. Such consulting fee shall be payable each year in advance. 

        C.    Records.    CryoLife shall maintain a true and correct set of records pertaining to commercial sales of Adhesive
and license revenues obtained from the licenses of the Adhesive. CryoLife shall be obliged to maintain records relating to any year for a period of five years. CryoLife agrees to permit an auditor
selected by Dr. Kowanko and reasonably acceptable to CryoLife to have access during normal business hours to such records to determine the correctness of any report and/or royalty payment made
under this Agreement. In the event that the audit reveals an underpayment of royalty by more than 7%, the cost of the audit shall be paid by CryoLife. Such accountant shall maintain in confidence, and
shall not report to Dr. Kowanko or others, any information concerning CryoLife or its operations or properties other than information directly relating to the correctness of such reports and
payments. 

        IV.    Representations of Dr. Kowanko.    Dr. Kowanko hereby represents and warrants that he
independently developed the Technology, that no university or governmental agency with or for whom Dr. Kowanko works or has worked in the past, or any student or employee thereof (other than
Dr. Kowanko), has any right, title or interest in or to the Technology, and that Dr. Kowanko has the authority to enter into and perform his obligations under this Agreement.
Dr. Kowanko further represents and warrants that he knows of no other compound or adhesive similar to the Adhesive or which provides the same or substantially similar functionality.
Dr. Kowanko warrants that said Technology has not been assigned, licensed, pledged, mortgaged or conveyed in whole or in part to any third party. Dr. Kowanko warrants that he has no
agreement with any third party which conflicts with his obligations to CryoLife under this Agreement. Dr. Kowanko does not warrant that the practice of the Patent or the use by CryoLife of the
Technology does not infringe or impinge upon any patent rights of others. 

        V.    Indemnification.    Subject to the accuracy of the representations and warranties of Dr. Kowanko set
forth elsewhere in this Agreement and the provisions of Section 6 below, CryoLife shall indemnify, defend, and hold Dr. Kowanko harmless from and against any and all damages, liability,
losses, and expenses incurred by Dr. Kowanko arising our of any claim, lawsuit, action or proceeding (collectively, "Claim") against Dr. Kowanko by a third party based upon the
production, distribution, or marketing by CryoLife of the Technology. As between the parties hereto, CryoLife shall defend, settle, or compromise all litigation (including action, suits and
proceedings before judicial or administrative tribunals, and arbitration proceedings), in which CryoLife, or its vendees, are charged by virtue of the manufacture, use or sale of Products or the use
of the Technology under this Agreement with infringement of any patent held by any third party. 

        VI.    Liability.    

        A.    Infringement; Misappropriation.    Dr. Kowanko warrants that he has received no notice that the
manufacture, use, or sale of any Products or the use of Technology is an infringement or misappropriation of the right of any third party and that to the best of his knowledge and belief, the
manufacture, use, or sale of Products or the use of the Technology is not an infringement or misappropriation of the rights of any third party. In the event CryoLife is obliged to defend any action
for such infringement or misappropriation of any patents held by any third party, Dr. Kowanko shall provide such assistance, including the furnishing of documents and information and the
execution of all necessary documents as CryoLife may reasonably require, but under no circumstances does Dr. Kowanko warrant or guarantee that the Products or the Technology is not or will not
be in infringement or misappropriation of any patent rights of any third party. No monies received by Dr. Kowanko from CryoLife shall be returned to CryoLife in the event of a third party suit,
whether or not it is successful. Dr. Kowanko does not warrant or represent that the Products or the Technology is free of infringement of any patent that may be existent at any time and
Dr. Kowanko does not offer or extend any indemnity for infringement of any patent, including those which may at any time be in existence at a place of business of CryoLife or the place of
manufacture of the Products. 

        B.    Disclaimer of Liability.    In no event shall Dr. Kowanko be liable for: (a) special, indirect,
incidental or consequential damages, or (b) any damages whatsoever resulting from the loss of use, data or profits arising out of or in connection with this Agreement or the use or performance
of any Technology, whether in an action based on contract or tort, including negligence. Dr. Kowanko shall not be liable for property damage or personal injury, including death, resulting from
the act done or not done in connection with an obligation assumed by either Dr. Kowanko or CryoLife hereunder other than an act done or not done as a result of willful wrongdoing or negligence
of Dr. Kowanko as determined by a court of law. 

        VII.    Prevention of Infringement.    Dr. Kowanko will assist CryoLife in connection with any actions by
CryoLife to prevent or stop any infringement or misappropriation by others of the Technology. CryoLife shall reimburse Dr. Kowanko for Dr. Kowanko's necessary and reasonable
out-of-pocket costs incurred in cooperating with Cryolife, at CryoLife's request, with respect to litigation hereunder. 

        VIII.    Confidentiality.    Dr. Kowanko shall keep confidential and shall not disclose or otherwise permit
access to the Trade Secrets to any other entity without CryoLife's prior written approval and will limited access to Know-How to the extent reasonably possible. Dr. Kowanko agrees to submit to
CryoLife's publications review committee any articles or writings he proposes to publish and to permit the committee a reasonable period of time consistent with its general practices to review such
material and to require deletions of confidential or proprietary information prior to publication or to delay publication up to nine months for the convenience of CryoLife. Dr. Kowanko may, if
he chooses, become a member of the committee as part of his consulting services to CryoLife. If Dr. Kowanko disagrees as to whether material is confidential or proprietary so as to permit the
committee to require its deletion from publishable material, Dr. Kowanko may submit his disagreement to arbitration conducted by two qualified scientists, one each selected by
Dr. Kowanko and CryoLife, for resolution. Unless the parties agree to other procedures, the arbitration will be conducted in accordance with the 

rules
of the American Arbitration Association. Each party shall bear its own costs associated with arbitration. 

        IX.    Consulting Services.    Dr. Kowanko shall provide consulting services to CryoLife for a period of five
years following the date of this Agreement on those projects described in (a) that certain letter dated October 6, 1995 from Dr. Kowanko to April L. O'Hara at CryoLife and
(b) that certain letter dated October 6, 1995 from Dr. Kowanko to Dr. Brenda Smith Morse at CryoLife, copies of each of which are attached hereto as  Exhibit B, and on such other
projects as may be proposed by Dr. Kowanko and approved by CryoLife. Dr. Kowanko shall devote
sufficient time and attention to the performance of services hereunder to complete the projects agreed to by CryoLife and Dr. Kowanko within such time frames as CryoLife may reasonably assign.
After the initial five-year period, Dr. Kowanko agrees to continue to provide consulting services to CryoLife pursuant to this Section 9 on a year to year basis, provided
(1) neither Dr. Kowanko nor CryoLife has notified the other in writing at least 60 days prior to the end of the then current consulting term and (ii) the parties have
agreed upon a consulting fee to be payable for Dr. Kowanko's services during the extended term. 

        X.    Patent Responsibilities.    CryoLife shall have the sole right, at its sole cost and expense, to take any action
in connection with the preparation, filing, and maintenance of any patents and patent applications, including any continuations, continuations-in-part, substitutions, reissues, and extensions thereof,
with respect to the Technology. Dr. Kowanko shall assist CryoLife, at CryoLife's cost and expense, in connection with any such efforts. 

        XI.    General Provisions.    

        A.    Entire Agreement.    This Agreement constitutes the entire agreement and understanding of the parties with
respect to the Technology and supersedes and terminates all other prior commitments, arrangements, or understandings, both oral and written between the parties with respect to the Technology,
including, without limitation, the Technology Investigation and Option Agreement dated June 15, 1993 between the parties and the TA Agreement. 

        B.    Modification.    This Agreement may not be modified or amended except by an instrument in writing executed by
each of the parties. 

        C.    Binding.    This Agreement shall be binding upon and inure to the benefit of the parties and their respective
successors and assigns. 

        D.    Governing Law.    This Agreement shall be governed and construed in accordance with the laws of the State of
Georgia. 

        E.    Notices.    Any notices or other communications required or permitted hereunder shall be in writing and shall be
sent by (a) personal delivery (including delivery by Federal Express or similar overnight courier), (b) mailed by registered or certified mail, return receipt requested, postage prepaid,
or (c) transmitted by facsimile, telex, or telecopy to the numbers set forth below and with originals of such transmissions sent by registered or certified mail. Notices shall be sent to the
addresses as set forth below or to such other addresses as may be hereafter furnished by one party to the other party in compliance with the terms, hereof. 

	 	If to Dr. Kowanko:	at the address set forth for Dr. Kowanko

in the first paragraph of this Agreement
	

 	

If to CryoLife:	

at the address set forth for CryoLife

in the first paragraph of this Agreement

Notices
shall be effective (a) upon receipt by the addressee, if sent by personal delivery or mail, or (b) upon transmission, if sent by telecopy, telex, or facsimile. 

        F.    Waiver.    None of the provisions of the Agreement shall be deemed to have been waived by any act or
acquiescence on the part of either party, their agents or employees, but may be waived only by instruments in writing signed by an authorized officer of the respective party. No waiver of any
provision of this Agreement shall constitute a waiver of any other provision or of the same provisions on another occasion. 

        G.    Counterparts.    This Agreement may be executed simultaneously in two or more counterparts, each of which shall
be deemed an original an all of which together shall constitute but one and the same instrument. 

        IN
WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed as of the date set forth herein by their duly authorized representatives. 

	

Sworn to and subscribed before me

the      day of                , 1996.	
 	

 	

 
	

 	

 	
 	

 	

 
	

  
  
 Notary Public	

 	
 	

  
 NICHOLAS KOWANKO, Ph.D.
	

(Notarial Seal)	
 	

 	

 
	My commission expires:	  
	 	 	 
	

Sworn to and subscribed before me

the 8th day of August, 1996.	
 	

CRYOLIFE, INC.
	

/s/  SUZANNE K. GABBERT      
	
 	

By:	

[Illegible]

	Suzanne K. Gabbert
 Notary Public	 	Title:	President/CEO

	

(Notarial Seal)

My commission expires:	

Notary Public, Cobb County, Georgia

My Commission Expires

Sept. 13, 1996.
	
 	

 	

 

        F.    Waiver.    None of the provisions of the Agreement shall be deemed to have been waived by any act or
acquiescence on the part of either party, their agents or employees, but may be waived only by instruments in writing signed by an authorized officer of the respective party. No waiver of any
provision of this Agreement shall constitute a waiver of any other provision or of the same provisions on another occasion. 

        G.    Counterparts.    This Agreement may be executed simultaneously in two or more counterparts, each of which shall
be deemed an original an all of which together shall constitute but one and the same instrument. 

        IN
WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed as of the date set forth herein by their duly authorized representatives. 

	

Sworn to and subscribed before me

the 24th day of July, 1996.	
 	

 	

 
	

 	

 	
 	

 	

 
	

/s/  GAIL L. SMITH      
  
 Notary Public	

 	
 	

/s/  NICHOLAS KOWANKO      
 NICHOLAS KOWANKO, Ph.D.
	

(Notarial Seal)

My commission expires:	

GAIL L. SMITH

Notary Public, STATE OF NORTH DAKOTA

My Commission Expires

FEB 26, 2002
	
 	

 	

 
	

Sworn to and subscribed before me

the      day of                , 1996.	
 	

CRYOLIFE, INC.
	

  
	
 	

By:	

  

	  
 Notary Public	 	Title:	  

	

(Notarial Seal)

My commission expires:	

  
	
 	

 	

 

EXHIBIT A  

 Definition of Adhesive  

        An adhesive composition, primarily intended as tissue adhesive, comprise of dialdehydes and proteinaceous material, and methods for its use. The adhesive property
is gained primarily by chemical reaction of these components with each other. "Adhesive" includes all inventions described in the Patents, which the parties acknowledge include all those patents and
patent applications described on the attached Nicholas Kowanko Patent Inventory dated March 13, 1996. 

QuickLinks

AMENDED AND RESTATED TECHNOLOGY ACQUISITION AGREEMENTQuickLinks
 -- Click here to rapidly navigate through this document

 
 

Exhibit 10.05    
    

DEXCOM, INC.

AMENDED AND RESTATED EXECUTIVE CHANGE OF CONTROL AGREEMENT  

        THIS AMENDED AND RESTATED EXECUTIVE CHANGE OF CONTROL AGREEMENT (the
"Agreement") is made as of January 31, 2005, between DexCom, Inc., a Delaware corporation (the
"Company") and Andy Rasdal ("Executive"). 

        WHEREAS, the Company and Executive are parties to that certain Executive Change of Control Agreement dated January 2, 2002 (the  "Prior Change of Control Agreement") and now desire to amend and restated that agreement to extend the vesting acceleration provisions of
Section 1(a) thereof to all five (5) of Executive's currently outstanding stock option grants; 

        WHEREAS, capitalized terms used herein shall have the meanings set forth in Section 2 herein; 

        WHEREAS, the Company, by means of this Agreement, seeks (i) to continue to retain the services of Executive, and (ii) to
provide incentives for Executive to exert maximum efforts for the success of the Company even in the face of a potential Change of Control; and 

        WHEREAS, the Company desires to provide Executive with protection of certain benefits in the event of a Change of Control. 

        NOW, THEREFORE, in consideration of the mutual covenants and promises set forth herein, the Company and Executive hereby agree as follows: 

        1.     ACCELERATION IN THE EVENT OF A CHANGE OF CONTROL. If a Change of Control occurs and either (x) your Continuous
Service has not terminated as of the date immediately prior to the effective date of such Change of Control or (y) your Continuous Service is involuntarily terminated without Cause during a
Change of Control Window, then the vesting and exercisability of the shares of Common Stock subject to each of the Stock Options shall be accelerated in full and any reacquisition or repurchase rights
held by the Company with respect to the shares of Common Stock subject to such acceleration shall lapse in full, as appropriate. 

        2.     DEFINITIONS. For purposes of this Agreement only, capitalized terms used herein shall have the following
meanings:

        (a)   "Affiliate" means any parent corporation or subsidiary corporation of the Company, whether now or
hereafter existing, as those terms are defined in Section 422(e) and (f) respectively, of the Code. 

        (b)   "Cause" means that you have engaged in (i) willful misconduct or gross negligence in the
performance of your duties; (ii) a material breach of your Proprietary Information and Inventions Agreement; or (iii) the commission of a felony affecting the Company or its business. 

        (c)   "Change of Control" means: (i) a sale of all or substantially all of the assets of the
Company; (ii) the acquisition of the Company by another entity by means of any transaction or series of related transactions (including, without limitation, reorganization, merger or
consolidation but, excluding any merger effected exclusively for the purpose of changing the domicile of the Company) unless the Company's stockholders of record as constituted immediately prior to
such acquisition will, immediately after such acquisition (by virtue of securities issued as consideration for the Company's acquisition or otherwise) hold at least 50% of the voting power of the
surviving or acquiring entity; or (iii) any reorganization, merger or consolidation in which the corporation is not the surviving entity and whereby the rights, preferences and privileges of
the Company's Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock have been adversely affected. 

        (d)   "Change of Control Window" means the period (a) beginning 90 days prior to the
earlier of (i) the execution of a letter of intent relating to a Change of Control transaction, if any, or (ii) the execution of a definitive agreement with respect to a Change of
Control transaction; in 

 

either
case, provided that the Change of Control with the party to the letter of intent or definitive agreement is consummated within two (2) years following such execution, and
(b) ending on the date such Change of Control becomes effective. 

        (e)   "Code" means the Internal Revenue Code of 1986, as amended. 

        (f)    "Common Stock" means the common stock of the Company. 

        (g)   "Continuous Service" means that Executive's service with the Company or an Affiliate, whether as
an employee, Director or consultant, is not interrupted or terminated. Neither a change in the capacity in which Executive renders service to the Company or an Affiliate as an employee, Director or
consultant, nor a change in the entity for which Executive renders such service, shall be deemed to interrupt or terminate Executive Continuous Service provided that there is not otherwise any
interruption or termination of service. 

        (h)   "Director" means a member of the Board of Directors of the Company. 

        (i)    "Stock Options" means each of the five (5) currently outstanding options to purchase
shares of Common Stock of the Company held by Executive pursuant to the Company's 1999 Stock Option Plan as follows: 

	1)
	Option
to purchase 1,000,000 shares granted on 12/12/01;

	2)
	Option
to purchase 300,000 shares granted on 12/12/01;

	3)
	Option
to purchase 156,000 shares granted on 2/10/04;

	4)
	Option
to purchase 300,000 shares granted on 3/11/04; and

	5)
	Option
to purchase 366,000 shares granted on 12/24/04 

        3.     PARACHUTE PAYMENTS. If any payment or benefit Executive would receive pursuant to a Change of Control from the Company or
otherwise (a "Payment") would (i) constitute a "parachute payment" within the meaning of Section 280G of the Code, and (ii) but for
this sentence, be subject to the excise tax imposed by Section 4999 of the Code (the "Excise Tax"), then such Payment shall be reduced to the
Reduced Amount. The "Reduced Amount" shall be either (x) the largest portion of the Payment that would result in no portion of the Payment being
subject to the Excise Tax or (y) the largest portion, up to and including the total, of the Payment, whichever amount, after taking into account all applicable federal, state and local
employment taxes, income taxes, and the Excise Tax (all computed at the highest applicable marginal rate), results in Executive's receipt, on an after-tax basis, of the greater amount of
the Payment notwithstanding that all or some portion of the Payment may be subject to the Excise Tax. If a reduction in payments or benefits constituting "parachute payments" is necessary so that the
Payment equals the Reduced Amount, reduction shall occur in the following order unless Executive elects in writing a different order (provided, however,
that such election shall be subject to Company approval if made on or after the effective date of the event that triggers the Payment): reduction of cash payments; cancellation of accelerated vesting
of stock and other equity-based awards; reduction of employee benefits. In the event that acceleration of vesting of stock and other equity-based award compensation is to be reduced, such acceleration
of vesting shall be cancelled in the reverse order of the date of grant of Executive's stock and other equity-based awards unless Executive elects in writing a different order for cancellation. 

        The
accounting firm engaged by the Company for general audit purposes as of the day prior to the effective date of the Change of Control shall perform the foregoing calculations. If the
accounting firm so engaged by the Company is serving as accountant or auditor for the individual, entity or group effecting the Change of Control, the Company shall appoint a nationally recognized
accounting firm to make the determinations required hereunder. The Company shall bear all expenses with respect to the determinations by such accounting firm required to be made hereunder. 

2

 

        The
accounting firm engaged to make the determinations hereunder shall provide its calculations, together with detailed supporting documentation, to Executive and the Company within
fifteen (15) calendar days after the date on which Executive's right to a Payment is triggered (if requested at that time by Executive or the Company) or such other time as requested by
Executive or the Company. If the accounting firm determines that no Excise Tax is payable with respect to a Payment, either before or after the application of the Reduced Amount, it shall furnish the
Company and Executive with an opinion reasonably acceptable to Executive that no Excise Tax will be imposed with respect to such Payment. Any good faith determinations of the accounting firm made
hereunder shall be final, binding and conclusive upon Executive and the Company. 

        4.     ADJUSTMENTS UPON CHANGES IN CAPITAL STOCK. All references to the Stock Options referenced in this Agreement shall include
and shall be appropriately adjusted by the Company to reflect any stock split, stock dividend, stock combination or other change in the Common Stock which may be made by the Company after the date of
this Agreement. 

        5.     NOTICES. Any notices provided for in this Agreement shall be given in writing and shall be deemed effectively given upon
receipt or, in the case of notices delivered by the Company to Executive, five (5) days after deposit in the United States mail, postage prepaid, addressed to Executive at the address specified
in the corporate records of the Company or at such other address as Executive hereafter designates by written notice to the Company. 

6.     MISCELLANEOUS. 

        (a)   The rights and obligations of Executive under this Agreement may not be transferred or assigned without the prior written
consent of the Company. 

        (b)   This Agreement is meant to supplement the terms of the stock options covering the purchase or other acquisition of
securities by Executive (collectively, the "Securities Acquisition Agreements") described herein. To the extent that the terms and conditions of any
Securities Acquisition Agreement are inconsistent with the terms set forth herein, the terms and conditions of this Agreement shall be controlling. This Agreement shall not be superseded by any
subsequent agreement unless such subsequent agreement is in writing, signed by Executive and such subsequent agreement specifically states that it is intended to supersede this Agreement and
specifically references this "Executive Change of Control Agreement" by name. 

        (c)   Any failure by the Company or Executive to enforce any provision or provisions of this Agreement shall not in any way be
construed as a waiver of any such provision or provisions, nor prevent either the Company or Executive from thereafter enforcing each and every other provision of this Agreement. The rights granted
the Company and Executive herein are cumulative and shall not constitute a waiver of either the Company's or Executive's right to assert all other legal remedies available to it under the
circumstances. 

        (d)   Executive agrees upon request to execute any further documents or instruments necessary or desirable to carry out the
purposes or intent of this Agreement. 

        (e)   In case any provision of this Agreement shall be invalid, illegal or unenforceable, the validity, legality and
enforceability of the remaining provisions shall not in any way be affected or impaired. 

        (f)    Subject to the provisions of subsection 6(b) herein, this Agreement, in whole or in part, may be modified, waived or
amended upon the written consent of the Company and Executive. 

        (g)   By Executive's signature below, Executive represents that he is familiar with the terms and provisions of this Agreement,
and hereby accepts this Agreement subject to all of the terms and provisions set forth herein. Executive has reviewed this Agreement in its entirety, has had an 

3

 

opportunity
to obtain the advice of counsel prior to executing this Agreement and fully understands all provisions of this Agreement. 

        7.     GOVERNING LAW. This Agreement shall be governed by, and construed in accordance with, the laws of the State of California,
regardless of the law that might be applied under applicable principles of conflicts of law. 

        8.     COUNTERPARTS. This Agreement may be executed in one or more counterparts, each of which shall be deemed an original, but
all of which shall constitute one instrument. 

        9.     PRIOR CHANGE OF CONTROL AGREEMENT. This Agreement amends and restates the Prior Change of Control Agreement in its
entirety, the terms and conditions of which are superceded by this Agreement. 

	
EXECUTIVE	
 	

DEXCOM, INC.
	

/s/  ANDY RASDAL      
 Andy Rasdal	
 	

/s/  DONALD L. LUCAS      
 Donald L. Lucas, Chairman of the Board
	 	 	 

[SIGNATURE PAGE TO AMENDED AND RESTATED EXECUTIVE CHANGE OF CONTROL AGREEMENT.]

4

QuickLinks

Exhibit 10.05

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00079-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00079-of-00352.parquet"}]]